CN108137508B - 5-ht2c受体激动剂和组合物及使用方法 - Google Patents

5-ht2c受体激动剂和组合物及使用方法 Download PDF

Info

Publication number
CN108137508B
CN108137508B CN201680058247.6A CN201680058247A CN108137508B CN 108137508 B CN108137508 B CN 108137508B CN 201680058247 A CN201680058247 A CN 201680058247A CN 108137508 B CN108137508 B CN 108137508B
Authority
CN
China
Prior art keywords
compound
individual
formula
cyclopropane
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680058247.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108137508A (zh
Inventor
于尔格.莱曼
康拉德·费什廷吉
A·S·任
G·森普尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arena Pharmaceuticals Inc
Original Assignee
Arena Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharmaceuticals Inc filed Critical Arena Pharmaceuticals Inc
Publication of CN108137508A publication Critical patent/CN108137508A/zh
Application granted granted Critical
Publication of CN108137508B publication Critical patent/CN108137508B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680058247.6A 2015-07-31 2016-07-28 5-ht2c受体激动剂和组合物及使用方法 Expired - Fee Related CN108137508B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31
US62/199,382 2015-07-31
PCT/US2016/044426 WO2017023679A1 (en) 2015-07-31 2016-07-28 5-ht2c receptor agonists and compositions and methods of use

Publications (2)

Publication Number Publication Date
CN108137508A CN108137508A (zh) 2018-06-08
CN108137508B true CN108137508B (zh) 2021-08-27

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680058247.6A Expired - Fee Related CN108137508B (zh) 2015-07-31 2016-07-28 5-ht2c受体激动剂和组合物及使用方法

Country Status (14)

Country Link
US (4) US10272094B2 (enExample)
EP (1) EP3328835B1 (enExample)
JP (1) JP6789578B2 (enExample)
KR (1) KR20180031035A (enExample)
CN (1) CN108137508B (enExample)
AU (1) AU2016302755B2 (enExample)
BR (1) BR112018001707A2 (enExample)
CA (1) CA3002525A1 (enExample)
EA (1) EA039412B1 (enExample)
HK (1) HK1255850A1 (enExample)
IL (1) IL257107B (enExample)
MA (1) MA42527A (enExample)
MX (1) MX375045B (enExample)
WO (1) WO2017023679A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016302755B2 (en) * 2015-07-31 2020-09-10 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220410894A1 (en) * 2021-06-29 2022-12-29 Tusimple, Inc. Systems and methods for operating an autonomous vehicle
EP4416027A1 (en) 2021-10-14 2024-08-21 Tusimple, Inc. Systems and methods for operating an autonomous vehicle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
CN100379735C (zh) * 2002-04-25 2008-04-09 惠氏公司 用作抗精神病和抗肥胖药物的1,2,3,4,7,8-六氢-6h-[1,4]二氮杂庚因并[6,7,1-ij]喹啉衍生物
CN101486677A (zh) * 2002-04-12 2009-07-22 阿伦纳药品公司 5ht2c受体调节剂
CN101792417A (zh) * 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
EP2824106A1 (en) * 2012-03-06 2015-01-14 Takeda Pharmaceutical Company Limited Tricyclic compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
EP2510949A4 (en) * 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
AR092568A1 (es) * 2012-09-14 2015-04-22 Abbvie Deutschland Derivados triciclicos de quinolinas y de quinoxalinas
AU2016302755B2 (en) 2015-07-31 2020-09-10 Arena Pharmaceuticals, Inc. 5-HT2C receptor agonists and compositions and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101486677A (zh) * 2002-04-12 2009-07-22 阿伦纳药品公司 5ht2c受体调节剂
CN100379735C (zh) * 2002-04-25 2008-04-09 惠氏公司 用作抗精神病和抗肥胖药物的1,2,3,4,7,8-六氢-6h-[1,4]二氮杂庚因并[6,7,1-ij]喹啉衍生物
CN101792417A (zh) * 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
EP2824106A1 (en) * 2012-03-06 2015-01-14 Takeda Pharmaceutical Company Limited Tricyclic compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1,9-Alkano-Bridged 2,3,4,5-Tetrahydro-1H-3-benzazepines with Affinity for the α2-Adrenoceptor and the 5-HT1A Receptor;Robin D. Clark et al.;《J. Med. Chem.》;19901231;第33卷(第2期);第633-641页 *
5-羟色胺5-HT2C受体激动剂抑制吗啡依赖小鼠纳洛酮诱导的戒断行为;吴县 等;《中国药理学通报》;20150316;第31卷(第4期);第518-523页 *

Also Published As

Publication number Publication date
CN108137508A (zh) 2018-06-08
IL257107A (en) 2018-03-29
US11395824B2 (en) 2022-07-26
CA3002525A1 (en) 2017-02-09
US20180214455A1 (en) 2018-08-02
US20200383993A1 (en) 2020-12-10
AU2016302755A1 (en) 2018-03-15
HK1255850A1 (zh) 2019-08-30
MX2018001380A (es) 2018-06-15
US20230055376A1 (en) 2023-02-23
EA201890402A1 (ru) 2018-09-28
IL257107B (en) 2021-03-25
EP3328835A1 (en) 2018-06-06
US10272094B2 (en) 2019-04-30
MX375045B (es) 2025-03-06
JP6789578B2 (ja) 2020-11-25
WO2017023679A1 (en) 2017-02-09
AU2016302755B2 (en) 2020-09-10
US20200078368A1 (en) 2020-03-12
US10624900B2 (en) 2020-04-21
NZ739883A (en) 2021-03-26
EP3328835B1 (en) 2022-10-12
JP2018522025A (ja) 2018-08-09
BR112018001707A2 (pt) 2018-09-18
EA039412B1 (ru) 2022-01-25
KR20180031035A (ko) 2018-03-27
MA42527A (fr) 2021-04-07

Similar Documents

Publication Publication Date Title
CN108137508B (zh) 5-ht2c受体激动剂和组合物及使用方法
CN107873030B (zh) 5-ht2c受体激动剂和组合物及使用方法
US11608339B2 (en) 5-HT2C receptor agonists and compositions and methods of use
WO2015066344A1 (en) 5-ht2c receptor agonists and compositions and methods of use
HK1244005A1 (en) 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) ５－ＨＴｃ受體促效劑
HK40010293B (en) 5-ht2c receptor agonists and compositions and methods of use
HK40010293A (en) 5-ht2c receptor agonists and compositions and methods of use
NZ739883B2 (en) 5-ht2c receptor agonists and compositions and methods of use
NZ737412B2 (en) 5-ht2c receptor agonists and compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210827

CF01 Termination of patent right due to non-payment of annual fee